Back to search results
NCT07226180

Development and Application of Patient-Derived Models of Cancer

Enrolling by Invitation
Not specifiedAges 18+Observational
Certis Oncology Solutions, Inc
~40 participants
Updated 2026-03-18 on ClinicalTrials.gov

At a glance

Recruiting sites
0 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
PDX Tumor Growth
Measured over 180 days

Conditions

Cancer

Explore related trials

Solid Neoplasm

NCT07226180

Where you'd take part

This study runs at 3 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Hoag Health Center Newport Beach

    Newport Beach, Californiano site contact published

  • Hoag Hospital Irvine

    Irvine, Californiano site contact published

  • Hoag Memorial Hospital Presbyterian

    Newport Beach, Californiano site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Solid tumor patients stage 2-4.
Cancer patients who have been previously treated or shown resistance or refraction to standard-of-care therapies and where the implicated tissue has not been irradiated in the ten (10) weeks prior to excision.
Patients with tumors are amenable to biopsy or surgery for fresh tissue and blood procurement as part of routine clinical care
Patients must be referred by a healthcare professional
Willingness for tissue samples used in future research
Signed informed consent
Willingness to share diagnosis, available genetic/molecular profiling data, treatment history, and treatment outcome monitoring

Exclusion

Failure to provide informed consent
Inaccessible tumors for biopsy or unavailability of tumor tissue for research purposes
Subjects under the age of 18
Subjects with cognitive impairment
Pregnant subjects
Contraindications to undergoing a biopsy procedure
No prior treatments, naive

What this trial measures

  • PDX Tumor Growth180 days

    The primary outcome of this study is the successful engraftment of patient-derived xenograft (PDX) tumors in the study animals. Engraftment success will be assessed by quantifying tumor growth using caliper measurements and/or magnetic resonance imaging (MRI). Successful engraftment will be defined as measurable and sustained tumor growth consistent with the characteristics of the original patient tumor.